CytoDyn Appoints Seenu Srinivasan as Executive Director of CMC Regulatory Affairs
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company") announced today the appointment of Seenu Srinivasan, Ph.D., as Executive Director-CMC Regulatory Affairs.
August 27, 2021
by firstwordpharma
Monoclonal antibody prevents HIV infection in monkeys, study finds
An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows.
June 10, 2021
by worldpharmanews
CytoDyn to seek regulatory approval for Covid-19 drug Vyrologix
CytoDyn is set to submit the results from the Phase III CD12 clinical trial of Vyrologix (leronlimab-PRO 140), seeking potential regulatory approval for the drug to treat severe to critically ill patients with Covid-19.
May 20, 2021
by pharmaceutical-technology
CytoDyn and Biomm enter leronlimab supply agreement
CytoDyn (CYDY) and Biomm have signed an exclusive supply and distribution agreement that will enable the latter to market CCR5 antagonist leronlimab (PRO 140) in Brazil on receiving regulatory approval.
April 9, 2021
by pharmaceutical-technology
Ajinomoto Bio-Pharma Services announces manufacturing partnership with CytoDyn for drug product used
The company provides high-quality drug product aseptic fill finish services for CytoDyn.
May 6, 2020
by expresspharma
Vyera licences HIV treatment from CytoDyn
Vyera Pharmaceuticals has entered agreements with CytoDyn to commercialise human immunodeficiency viruses (HIV) treatment leronlimab (PRO 140) in the US.
December 23, 2019
by pharmaceutical-technology
CytoDyn Evaluates Leronlimab for Triple-Negative Breast Cancer
FDA grants CytoDyn Fast Tract Designation to evaluate leronlimab in combination with carboplatin for the treatment of triple-negative breast cancer.
June 12, 2019
by contractpharma